))
Additional Advances in Graft-Versus-Host Disease Research and Clinical Trials: Shernan Holtan, MD
Manage episode 357636646 series 3456244
A tartalmat a i3 Health and I3 Health biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a i3 Health and I3 Health vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.
In 2022, Dr. Shernan Holtan, Associate Professor at the University of Minnesota Medical School, recorded a CME/NCPD activity centered on new therapeutic avenues for improved patient outcomes in graft-versus-host-disease (GVHD). Recently, at the American Society of Hematology (ASH) Annual Meeting, she presented results of the BMT CTN 1703 trial, which investigated the efficacy of a GVHD prophylaxis regimen. While there, Dr. Holtan sat down with Oncology Data Advisor to discuss the potential of these results to change GVHD prophylaxis, as well as the other significant GVHD research presented at the meeting. Click here to view and claim credit for New Opportunities for Improved Patient Outcomes in Graft-Versus-Host Disease, an accredited CME/NCPD activity provided by i3 Health: https://i3health.com/gvhd
…
continue reading
41 epizódok
Megosztás
